
KSI-301 Anti-VEGF Antibody Biopolymer Conjugate for Retinal Vein Occlusion: Primary 24-Week Efficacy and Safety Outcomes of the BEACON Phase III Pivotal Study
Author: Arshad Khanani
Co-authors: Jason S Ehrlich, Daniel Janer, Pablo Velazquez-Martin, Rezi Zawadzki, Victor Perlroth